Table 1. Patient Characteristics in the Safety Seta.
| Characteristic | Etomidate group (n = 967) | Propofol group (n = 950) |
|---|---|---|
| Age, mean (SD), y | 70.3 (4.0) | 70.6 (4.2) |
| Sex, No. (%) | ||
| Female | 389 (40.2) | 417 (43.9) |
| Male | 578 (59.8) | 533 (56.1) |
| Height, mean (SD), cm | 164.2 (7.4) | 163.6 (8.0) |
| Weight, mean (SD), kg | 62.7 (9.3) | 62.6 (10.0) |
| BMI, mean (SD) | 23.2 (2.8) | 23.3 (2.8) |
| SBP, mean (SD), mm Hg | 134.1 (15.7) | 134.7 (15.2) |
| ASA Physical Status Classification System class, No. (%) | ||
| 1 | 23 (2.4) | 21 (2.2) |
| 2 | 719 (74.4) | 684 (72.0) |
| 3 | 225 (23.3) | 245 (25.8) |
| History of comorbidity, No. (%) | 26 (2.7) | 25 (2.6) |
| History of anesthesia, No. (%) | 9 (0.9) | 11 (1.2) |
| History of allergy, No. (%) | 2 (0.2) | 2 (0.2) |
| Fluid input, median (IQR), mL | 900 (600-1100) | 900 (600-1200) |
| Surgery type, No. (%) | ||
| Gastrointestinal | 573 (59.3) | 570 (60.0) |
| Hepatobiliary | 394 (40.7) | 380 (40.0) |
| Duration of surgery, median (IQR), h | 2.1 (1.2-3.0) | 2.0 (1.1-3.1) |
| Duration of anesthesia, median (IQR), h | 2.4 (1.4-3.5) | 2.5 (1.4-3.5) |
| Dose of sufentanil, median (IQR), μg | 35.0 (30.0-40.0) | 35.0 (30.0-40.0) |
| Dose of cisatracurium, median (IQR), mg | 24.0 (17.2-31.0) | 23.3 (17.0-30.8) |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); SBP, systolic blood pressure.
a
The safety set comprised all patients who received the randomized intervention, underwent planned surgery, and continued to consent to follow-up.